Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 16, 2024

Navigating Biosimilar Uptake in New Patients

The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.

Episodes in this series

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

A panel of 4 experts on biosimilars

EP. 7 Private Label Biosimilars

EP. 8 Biosimilars in the Commercial Sector

EP. 8 Biosimilars in the Commercial Sector

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 11 Unmet Needs and Future Initiatives

EP. 11 Unmet Needs and Future Initiatives

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 13 Foreseeable Biosimilar Trends

EP. 13 Foreseeable Biosimilar Trends

EP. 14 Legislative Support for Biosimilars

EP. 14 Legislative Support for Biosimilars

EP. 15 Key Takeaways for Biosimilar Utilization

EP. 15 Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

How do you direct new-start patients to a biosimilar? What about switching?
Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Road Ahead: Personalized Therapy, Combination Approaches, and Key Takeaways in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 20th 2026

SYNCHRONIZE-1 Through a Hepatologist's Lens: Liver Fat Reduction, Visceral Fat, and What Comes Next

ByNadege Gunn, MD

July 17th 2026

Navigating Treatment Sequencing and Defining Failure in Moderate-to-Severe Atopic Dermatitis

ByAngela J. Lamb, MD

July 17th 2026

Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH

ByNadege Gunn, MD

July 17th 2026

Emerging Data and the Future Treatment Landscape in Extrapulmonary Neuroendocrine Carcinoma: Novel Therapies, Algorithms, and Combination Strategies

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

July 13th 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Contextualizing Golcadomide's Efficacy Signal in the RRFL Landscape

The Role of Radiotherapy in Advanced Follicular Lymphoma